WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
investors@aclaristx.com
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 20, 2024) - BioHarvest Sciences Inc. (CSE:…
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…
SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or…
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in…
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary…
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase…